Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact email@example.com.
Safety and Effectiveness of a Non-Electric Infant Warmer for Hypothermia in Rwanda: A Cluster-Randomized Stepped-Wedge Trial
21 Pages Posted: 4 Feb 2021More...
Background: Neonatal hypothermia is a common source of morbidity and mortality in low resource settings. We developed the Dream Warmer, a low cost, re-usable non-electric infant warmer to prevent and treat hypothermia.
Methods: We conducted a cluster-randomized stepped-wedge trial. The primary aim was to assess the effect on overall euthermia rates of introducing the warmer compared to standard of care in rural Rwandan hospitals. The secondary aims were to assess effects of warmer introduction on mortality, as well as the safety and feasibility of the warmer. Ten district hospitals participated in the study. Patients were eligible to use the warmer if they were 1) hypothermic (temp < 36·5 o C) or 2) or at risk of hypothermia (weight < 2·5 kg or estimated post menstrual age < 35 weeks) when Kangaroo Mother Care was not available. An encounter was defined as the data from an individual infant on a single day.
Findings: Over the study period, 3179 patients were enrolled across the ten neonatal wards, yielding 12,748 encounters; 464 unique infants used the warmer 892 times, 79% eligible due to hypothermia. Because of limited study nurse resources, the warmer was used in only 18% of eligible encounters. Despite this low rate of warmer use, the rate of euthermia rose from 51% (95% CI 50−52%) of encounters pre-intervention to 67% (66−68%) post-intervention; p< 0·0001. Among the encounters in which the warmer was used, only 11% (9-13%) remained hypothermic. While mortality rates pre- and post-intervention did not change, mortality rate among those who used the warmer was significantly lower than among those who did not (0·9% vs 2·8%, p=0·01). Use of the warmer did not affect hyperthermia rates. There were no safety concerns or instances of incorrect warmer use.
Interpretation: Introduction of the warmer increased rates of euthermia with no associated safety concerns.
Trial Registration: Trial of a Non Electric Infant Warmer for Prevention and Treatment of Hypothermia in Rwanda [NCT03890211].
Funding Statement: The study was funded by the Banyan Gates Foundation.
Declaration of Interests: Anne Hansen is the President and CEO, and Ashok Gadgil is member of the Board, of Global Newborn Solutions, a nonprofit founded to manufacture and distribute the Dream Warmer. Neither has ever received any financial compensation for their role. No conflicts of interest exist for other authors.
Ethics Approval Statement: Informed consent was obtained from caretakers of all study participants from whom we only collected data. If an infant became eligible to use the warmer, a second consent was requested specifically for warmer use. The study was approved by human research review: BCH Institutional Review Board (IRB-P00030705), the Rwanda National Ethics Committee (reference # 0076/RNEC 2018), Rwanda National Health Research Committee (reference # 514) and the Rwanda MOH.
Suggested Citation: Suggested Citation